Severity
Moderate
FDA Drug recall · Reported January 6, 2021
Lack of assurance of sterility: 13 vials were discovered to have faulty crimps.
Imprimis Njof, LLC recalled Dexamethasone - Moxifloxacin PF Injection (1/5) mg/mL, Imprimis Rx Volume: 1mL/vial, Impr… - a moderate-severity action.
Dexamethasone - Moxifloxacin PF Injection (1/5) mg/mL, Imprimis Rx Volume: 1mL/vial, Impr… was recalled by Imprimis Njof, LLC in January 6, 2021. Reason: Lack of assurance of sterility: 13 vials were discovered to have faulty crimps.. Check the official notice for the remedy. Verify recall #D-0177-2021 with the FDA Drug before acting.
The recall
Imprimis Njof, LLC issued this moderate-severity FDA Drug recall-Lack of assurance of sterility: 13 vials were discovered to have faulty crimps..
Sourced from official FDA Drug enforcement records. Verify recall #D-0177-2021 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-0177-2021) was formally reported on January 6, 2021, with the manufacturer initiating the action on December 17, 2020. It is classified under Moderate severity (Class II), with a current status of Terminated. Imprimis Njof, LLC is listed as the recalling firm, operating out of Ledgewood, NJ. Federal records list the affected scope as 6520 vials.
The documented reason for this recall is: Lack of assurance of sterility: 13 vials were discovered to have faulty crimps. Distribution data in the federal record shows the product reached: U.S.A. Nationwide. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 14,287 drugs & medications recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified moderate severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Moderate
Affected scope
6520 vials
Related Recalls
6
5 from same agency
Dexamethasone - Moxifloxacin PF Injection (1/5) mg/mL, Imprimis Rx Volume: 1mL/vial, Imprimis NJOF, LLC. 1705 Route 46 West, Unit 6B Ledgewood, NJ - 07852 (844)446-6979
Lack of assurance of sterility: 13 vials were discovered to have faulty crimps.
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Moderate (Class II) |
| Status | Terminated |
| Recall number | D-0177-2021 |
| Date reported | January 6, 2021 |
| Date initiated | December 17, 2020 |
| Recalling firm | Imprimis Njof, LLC |
| Firm location | Ledgewood, NJ |
| Affected scope | 6520 vials |
| Distribution | U.S.A. Nationwide |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
AbbVie Inc. · 2026-06-03
Llorens Pharmaceuticals International Division, Inc. · 2026-05-27
Safecor Health, LLC · 2026-05-27
IntegraDose Compounding Services LLC · 2026-05-27
Lupin Pharmaceuticals Inc. · 2026-05-27
Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported January 6, 2021. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.